Medication Treatment of ADHD in Pediatric Epilepsy

NCT ID
NCT07594652
Registry status
Recruiting
Study type
Interventional
Phase
Phase 4
Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: Use of JornayPM® to Treat ADHD in Pediatric Epilepsy

Enrollment: 25 participants (Estimated).

What is being studied

  • Intervention: Acids, Carbocyclic
  • Intervention: Carboxylic Acids
  • Intervention: Heterocyclic Compounds
  • Intervention: Heterocyclic Compounds, 1-Ring
  • Intervention: Methylphenidate
  • Drug: methylphenidate hydrochloride (Jornay PM)
  • Intervention: Organic Chemicals
  • Intervention: Phenylacetates
  • Intervention: Piperidines

Who may be eligible

Ages
6 Years to 17 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Inclusion criteria: * Established diagnosis of epilepsy that requires treatment with anti-seizure medication. * No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study. * Diagnosis of ADHD with functional impairment. * Good general health as determined by medical history and physical examination, including stable vital signs. * Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment. Exclusion Criteria: * • Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM® * Active substance abuse or dependence within 30 days of enrollment * Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months * DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others. * Current use of stimulants to treat ADHD * Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes. * Unstable cardiac illness such as arrythmias or cardiomyopathy. * Participation in a previous experimental drug study within 30 days of baseline visit. * Estimated IQ\<70 as indicated by clinical assessment to the degree that rating scales may be invalid * Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures

Study locations

1 study location is listed.

Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.

Countries: United States

  • Maryland, United States: 1

Sample of listed locations

  • Kennedy Krieger Institute — Baltimore, Maryland, 21205, United States — Recruiting

Study details

Start date
May 29, 2026
Primary completion date
December 1, 2030
Completion date
December 1, 2030
First posted
May 19, 2026

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07594652
Registry last updated
July 29, 2026
QualifiedStudies registry data refreshed
September 28, 2026
QualifiedStudies record fetched
September 28, 2026

View NCT07594652 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | ADHD studies | Clinical trial FAQ